Multidrug-resistant and extensively drug-resistant tuberculosis: Implications for the HIV epidemic and antiretroviral therapy rollout in South Africa

Journal of Infectious Diseases

Volumn 196, Issue SUPPL. 3, 2007, Pages

  Andrews, Jason R ^a   Shah, N Sarita ^b   Gandhi, Neel ^b   Moll, Tony ^c   Friedland, Gerald ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c Philanjalo and Church of Scotland Hospital   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIRETROVIRUS AGENT; CAPREOMYCIN; CIPROFLOXACIN; ETHAMBUTOL; ISONIAZID; KANAMYCIN; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFAMPICIN; STREPTOMYCIN;

ANTIBIOTIC RESISTANCE; CONFERENCE PAPER; DISEASE ASSOCIATION; HEALTH HAZARD; HEALTH PROGRAM; HEALTH STATUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION CONTROL; MORTALITY; PREVALENCE; PRIORITY JOURNAL; SOUTH AFRICA; TREATMENT FAILURE; TUBERCULOSIS; VIRUS TRANSMISSION; AIDS RELATED COMPLEX; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; METHODOLOGY; MICROBIOLOGY; REVIEW; VIROLOGY;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HIV INFECTIONS; HUMANS; SOUTH AFRICA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 39549115892     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/521121     Document Type: Conference Paper

References (63)

1. Zignol M, Hosseini MS, Wright A, et al. Global incidence of multidrug-resistant tuberculosis. J Infect Dis 2006; 194:479-85.
2. Iseman M. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993; 329:784-91.
3. Wells CD, Cegielski JP, Nelson LJ, et al. HIV infection and multidrug-resistant tuberculosis - the perfect storm. J Infect Dis 2007; 196(Suppl 1):S86-107.
4. Aziz MA, Wright A, Laszlo A, et al. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet 2006; 368:2142-54.
5. World Health Organization (WHO). Global tuberculosis control: surveillance, planning, financing: WHO report 2007. WHO/HTM/TB/2007.376. Geneva: WHO, 2007.
6. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368:1575-80.
7. Shah N, Wright A, Bai GH, et al. Worldwide emergence of extensively drug-resistant tuberculosis (XDR TB): global survey of second-line drug resistance among Mycobacterium tuberculosis isolates. Emerg Infect Dis 2007; 13:380-7.
8. World Health Organization (WHO). Towards universal access: scaling up priority HIV/AIDS interventions in the health sector; progress report, April, 2007. Geneva: WHO, 2007.
9. Joint United Nations Programme on HIV/AIDS (UNAIDS). 2006 Report on the global AIDS epidemic. Geneva: UNAIDS, 2006.
10. Weyer K, Kleeberg HH. Primary and acquired drug resistance in adult black patients with tuberculosis in South Africa: results of a continuous national drug resistance surveillance programme involvement. Tuber Lung Dis 1992; 73:106-12.
11. Davies GR, Pillay M, Sturm AW, Wilkinson D. Emergence of multidrug-resistant tuberculosis in a community-based directly observed treatment programme in rural South Africa. Int J Tuberc Lung Dis 1999; 3:799-804.
12. Weyer K, Groenewald P, Zwarenstein M, Lombard CJ. Tuberculosis drug resistance in the Western Cape. S Afr Med J 1995; 85:499-504.
13. Weyer K, Lancaster J, Balt E, Durrheim D. Tuberculosis drug resistance in Mpumalanga province, South Africa (abstract 669-PD). In: Proceedings of the Global Congress on Lung Health, 29th World Conference of the International Union against Tuberculosis and Lung Disease (Bangkok). Int J Tuberc Lung Dis 1998; 2:S165.
14. Wilkinson D, Pillay M, Davies GR, Sturm AW. Resistance to antituberculosis drugs in rural South Africa: rates, patterns, risks, and transmission dynamics. Trans R Soc Trop Med Hyg 1996; 90:692-5.
15. Churchyard GJ, Corbett EL, Kleinschmidt I, Mulder D, De Cock KM. Drug-resistant tuberculosis in South African gold miners: incidence and associated factors. Int J Tuberc Lung Dis 2000; 4:433-40.
16. Louw GE, Warren RM, Donald PR, et al. Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients. Int J Tuberc Lung Dis 2006; 10:802-7.
17. Victor TC, Streicher EM, Kewley C, et al. Spread of an emerging Mycobacterium tuberculosis drug-resistant strain in the Western Cape of South Africa. Int J Tuberc Lung Dis 2007; 11:195-201.
18. Weyer K, Lancaster J, Brand J, van der Walt M, Levin J. Survey of tuberculosis drug resistance in South Africa: 2001-2002. Pretoria, South Africa: Medical Research Council of South Africa, 2004.
19. Andrews J. Clinical predictors of drug resistance and mortality among tuberculosis patients in a rural South African hospital: a case-control study. New Haven, CT: Yale AIDS Program, Department of Internal Medicine, Yale University School of Medicine, 2007:79.
20. Moll A, Gandhi N, Andrews J, et al. Extensively drug-resistant (XDR) TB now more common than MDR TB in Tugela Ferry, KwaZulu Natal, South Africa. In: Program and abstracts of the 38th Union World Conference on Lung Health (Cape Town). Paris: International Union Against Tuberculosis and Lung Disease, 2007.
21. Moodley P, Moll A, Shah NS, et al. Multi- and extensively drug-resistant Mycobacterium tuberculosis in KwaZulu Natal. In: Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2007.
22. Basu S, Andrews J, Poolman EM, et al. The epidemic-level impact of preventing nosocomial transmission of extensively drug-resistant (XDR) tuberculosis in rural South African district hospitals. The Lancet 2007 (in press).
23. Campos PE, Suarez PG, Sanchez J, et al. Multidrug-resistant Mycobacterium tuberculosis in HIV-infected persons, Peru. Emerg Infect Dis 2003; 9:1571-8.
24. Gordin FM, Nelson ET, Matts JP, et al. The impact of human immunodeficiency virus infection on drug-resistant tuberculosis. Am J Respir Crit Care Med 1996; 154:1478-83.
25. Punnotok J, Shaffer N, Naiwatanakul T, et al. Human immunodeficiency virus-related tuberculosis and primary drug resistance in Bangkok, Thailand. Int J Tuberc Lung Dis 2000; 4:537-43.
26. Kenyon TA, Mwasekaga MJ, Huebner R, Rumisha D, Binkin N, Maganu E. Low levels of drug resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus co-epidemics in Botswana. Int J Tuberc Lung Dis 1999; 3:4-11.
27. World Health Organization (WHO). Anti-tuberculosis drug resistance in the world: third global report. WHO/International Union against Tuberculosis and Lung Disease Global Project on Anti-tuberculosis Drug Resistance Surveillance. WHO/HTM/TB/2004.343. Geneva: WHO, 2004.
28. Centers for Disease Control and Prevention. Multidrug-resistant tuberculosis outbreak on an HIV ward - Madrid, Spain, 1991-1995. MMWR Morb Mortal Wkly Rep 1996; 45:330-3.
29. Moro ML, Gori A, Errante I, et al. An outbreak of multidrug-resistant tuberculosis involving HIV-infected patients of two hospitals in Milan, Italy. Italian Multidrug-Resistant Tuberculosis Outbreak Study Group. AIDS 1998; 12:1095-102.
30. Frieden TR, Sherman LF, Maw KL, et al. A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes. JAMA 1996; 276:1229-35.
31. Tappero JW, Bradford WZ, Agerton TB, et al. Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clin Infect Dis 2005; 41:461-9.
32. Patel KB, Belmonte R, Crowe HM. Drug malabsorption and resistant tuberculosis in HIV-infected patients. N Engl J Med 1995; 332:336-7.
33. Chaisson RE, Clermont HC, Holt EA, et al. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Am J Respir Crit Care Med 1996; 154:1034-8.
34. Murray J, Sonnenberg P, Shearer SC, Godfrey-Faussett P. Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. Am J Respir Crit Care Med 1999; 159:733-40.
35. Ridzon R, Whitney CG, McKenna MT, et al. Risk factors for rifampin mono-resistant tuberculosis. Am J Respir Crit Care Med 1998; 157:1881-4.
36. Friedland G, Abdool Karim S, Abdool Karim Q, et al. Utility of tuberculosis directly observed therapy programs as sites for access to and provision of antiretroviral therapy in resource-limited countries. Clin Infect Dis 2004; 38(Suppl 5):S421-8.
37. Friedland G, Churchyard GJ, Nardell E, eds. Tuberculosis and HIV coinfection: current state of knowledge and research priorities. J Infect Dis 2007; 196(Suppl 1):S1-125.
38. Blower SM, Chou T. Modeling the emergence of the 'hot zones': tuberculosis and the amplification dynamics of drug resistance. Nat Med 2004; 10:1111-6.
39. Escombe AR, Oeser CC, Gilman RH, et al. Natural ventilation for the prevention of airborne contagion. PLoS Med 2007; 4:e68.
40. Lawn SD, Myer L, Bekker L-G, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006; 20:1605-12.
41. Bock NN, Jensen PA, Miller B, Nardell E. Tuberculosis infection control in resource-limited settings in the era of expanding HIV care and treatment. J Infect Dis 2007; 196(Suppl 1):S108-13.
42. World Health Organization (WHO). Guidelines for the prevention of tuberculosis in health care facilities in resource-limited settings. Geneva: WHO, 1999.
43. Johnson JL, Vjecha MJ, Okwera A, et al. Impact of human immunodeficiency virus type-1 infection on the initial bacteriologic and radiographic manifestations of pulmonary tuberculosis in Uganda. Makerere University-Case Western Reserve University Research Collaboration. Int J Tuberc Lung Dis 1998; 2:397-404.
44. Long R, Scalcini M, Manfreda J, Jean-Baptiste M, Hershfield E. The impact of HIV on the usefulness of sputum smears for the diagnosis of tuberculosis. Am J Public Health 1991; 81:1326-8.
45. Perlman DC, el-Sadr WM, Nelson ET, et al. Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression. The Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). The AIDS Clinical Trials Group (ACTG). Clin Infect Dis 1997; 25:242-6.
46. Green-Thompson R. South Africa. In: Program and abstracts of the Meeting of the Global XDR-TB Task Force, 9-10 October 2006 (Geneva). Geneva: World Health Organization, 2006.
47. South African Department of Health. The South African Tuberculosis Control Programme practical guidelines. Pretoria: South African Department of Health, 2000.
48. Rajbhandary SS, Marks SM, Bock NN. Costs of patients hospitalized for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2004; 8:1012-6.
49. Nathanson E, Lambregts-van Weezenbeek C, Rich ML, et al. Multidrug-resistant tuberculosis management in resource-limited settings. Emerg Infect Dis 2006; 12:1389-97.
50. Kawai V, Soto G, Gilman RH, et al. Tuberculosis mortality, drug resistance, and infectiousness in patients with and without HIV infection in Peru. Am J Trop Med Hyg 2006; 75:1027-33.
51. Munsiff SS, Ahuja SD, Li J, Driver CR. Public-private collaboration for multidrug-resistant tuberculosis control in New York City. Int J Tuberc Lung Dis 2006; 10:639-48.
52. van der Wal M, Weyer K, Lancaster J. A standardized approach to management of drug-resistant TB in South Africa [PowerPoint presentation]. South Africa Medical Research Council Expert Consultation on Drug-Resistant Tuberculosis. Johannesburg: Medical Research Council of South Africa, 2006.
53. Gandhi N, Moll A, Pawinski R, Zeller K, Lalloo U, Friedland G. Favorable outcomes of the integration of TB and HIV treatment in rural South Africa: the Sizonq'oba study (abstract MOPE0181). In: Program and abstracts of the XVIth International AIDS Conference (Toronto). Geneva: International AIDS Society, 2006.
54. Dean GL, Edwards SG, Ives NJ, et al. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 2002; 16:75-83.
55. Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr 2006; 43:42-6.
56. Friedland G, Abdool Karim S, Abdool Karim Q, et al. Utility of tuberculosis directly observed therapy programs as sites for access to and provision of antiretroviral therapy in resource-limited countries. Clin Infect Dis 2004; 38(Suppl 5):S421-8
57. Moore DAJ, Evans CAW, Gilman RH, et al. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med 2006; 355:1539-50.
58. Morgan M, Kalantri S, Flores L, Pai M. A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. BMC Infect Dis 2005; 5:62.
59. Pai M, Kalantri S, Pascopella L, Riley LW, Reingold AL. Bacteriophage-based assays for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a meta-analysis. J Infect 2005; 51:175-87.
60. Global XDR-TB Task Force working group. Management of XDR TB suspects in high and low HIV prevalence settings [PowerPoint presentation]. Meeting of the Global XDR-TB Task Force, 9-10 October 2006 (Geneva). Geneva, World Health Organization, 2006.
61. World Health Organization (WHO). Interim policy on collaborative TB/HIV activities. Geneva: WHO, 2004.
62. Holtz TH, Lancaster J, Laserson KF, Wells CD, Thorpe L, Weyer K. Risk factors associated with default from multidrug-resistant tuberculosis treatment, South Africa, 1999-2001. Int J Tuberc Lung Dis 2006; 10:649-55.
63. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348:119-28.